topotecan has been researched along with Neuroblastoma in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (7.45) | 18.2507 |
| 2000's | 39 (41.49) | 29.6817 |
| 2010's | 41 (43.62) | 24.3611 |
| 2020's | 7 (7.45) | 2.80 |
| Authors | Studies |
|---|---|
| Badel, JN; Bogart, E; Corradini, N; Cougnenc, O; Courbon, F; Defachelles, AS; Deley, MCL; Gambart, M; Giraudet, AL; Kolesnikov-Gauthier, H; Oudoux, A; Rault, E; Schleiermacher, G; Sevrin, F; Valteau-Couanet, D | 1 |
| Campagne, O; Daryani, VM; Gajjar, AJ; Naranjo, A; Park, JR; Stewart, CF; Wu, H; Wu, J | 1 |
| Carta, R; Cefalo, MG; D'Andrea, ML; De Ioris, MA; Del Baldo, G; Del Bufalo, F; Fabozzi, F; Garganese, MC; Giovannoni, I; Greco, AM; Locatelli, F; Mastronuzzi, A; Stracuzzi, A; Tangari, F; Villani, MF | 1 |
| Chan, MY; Chang, KTE; Chen, Y; Chen, Z; Choo, Z; Chua, YW; Hee, E; Iyer, P; Jain, S; Kuick, CH; Lam, JCM; Lian, DWQ; Lim, TKH; Ling, S; Loh, AHP; Low, SYY; Ng, EHQ; Ren, MH; Seng, MSF; Soh, SY; Syed Sulaiman, N; Syed, MF; Tan, AM; Tan, EEK; Tan, SH; Wong, MK; Yong, MH; Yong, YFL | 1 |
| Harrie, RP; Levin, AM; Owen, L | 1 |
| Bansal, D; Jain, R; Kakkar, N; Kapoor, R; Menon, P; Mittal, BR; Radhika, S; Samujh, R; Saxena, AK; Trehan, A; Varma, N | 1 |
| Benes, CH; Cai, J; Casey, C; Coon, C; Crowther, GS; D'Aulerio, A; Dalton, KM; Dozmorov, M; Faber, AC; Greninger, P; Hu, B; Jacob, S; Khan, QA; Krytska, K; Kurupi, R; Lochmann, TL; Mossé, YP; Sano, R; Souers, AJ | 1 |
| Kraal, KC; Tytgat, GA; van Dalen, EC; Van Eck-Smit, BL | 1 |
| Bogart, E; Chastagner, P; Cougnenc, O; Defachelles, AS; Ferry, I; Kolesnikov-Gauthier, H; Michon, J; Oudoux, A; Proust, S; Schleiermacher, G; Valteau-Couanet, D | 1 |
| Katowitz, WR; Revere, KE; Shen, A | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T | 1 |
| Ashraf, K; Baruchel, S; Gibson, P; Irwin, MS; Shaikh, F | 1 |
| Ferrer, F; Hla, T; Li, MH | 1 |
| Feng, C; Liu, Y; Tang, S; Wang, J; Yang, G | 1 |
| Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM | 1 |
| Chang, J; Wang, LZ; Zhang, YT; Zhong, XD | 1 |
| Carrasco, R; Cruz, O; de Torres, C; Guillen, A; Lavarino, C; Mañé, S; Mora, J; Parareda, A; Rios, J; Salvador, H; Suñol, M; Vancells, M | 1 |
| Caron, HN; Kam, B; Kraal, KC; Tytgat, GA; van Eck-Smit, BL; van Noesel, M | 1 |
| Bruchelt, G; Cabanillas Stanchi, KM; Handgretinger, R; Holzer, U | 1 |
| Augustyniak, E; Boratyn, E; Drożniak, J; Durbas, M; Górka, A; Horwacik, I; Kowalczyk, A; Krzanik, S; Rokita, H; Sawicka, A; Węgrzyn, P | 1 |
| Scorsone, K; Woodfield, SE; Zage, PE; Zhang, L | 1 |
| Hansel, TD; Infarinato, NR; Krytska, K; Makena, MR; Mossé, YP; Raman, P; Reynolds, CP; Ryles, HT; Sano, R; Song, MM | 1 |
| Ambros, IM; Ambros, PF; Blaha, J; Frank, N; Hohenegger, M; Kauer, M; Kromp, F; Ladenstein, R; Rifatbegovic, F; Schwarz, M; Taschner-Mandl, S; Weiss, T | 1 |
| Baruchel, S; Kumar, S; Marrano, P; Thorner, P; Wu, B; Zhang, L | 1 |
| Chaturvedi, NK; Coulter, DW; Joshi, SS; McGuire, TR; McIntyre, EM; Sharp, JG; Shukla, A | 1 |
| Kameoka, M; Nakamichi, K; Nukuzuma, C; Nukuzuma, S; Sugiura, S; Takegami, T; Tasaki, T | 1 |
| Carpentier, P; Clisant, S; Cougnenc, O; Defachelles, AS; Kolesnikov-Gauthier, H; Lervat, C; Oudoux, A | 1 |
| Amoroso, L; Bautista, F; Chevance, A; Gambart, M; Garaventa, A; Geoerger, B; Le Deley, MC; Moreno, L; Paoletti, X; Pearson, AD; Rubie, H; Valteau-Couanet, D; Varo, A; Vassal, G | 1 |
| Battaglia, F; Bosco, MC; Delfino, S; Ottaviano, C; Puppo, M; Ribatti, D; Varesio, L | 1 |
| Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y | 1 |
| Babich, JW; Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL | 1 |
| Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA | 1 |
| Gil, M; Horwacik, I; Kowalczyk, A; Kozbor, D; Odrowaz, Z; Rokita, H | 1 |
| Geoerger, B; Gerstenmeyer, A; Lagodny, J; Niemeyer, CM; Odenthal, E; Rössler, J; Vassal, G | 1 |
| Collins, C; Fister, KR; Key, B; Williams, M | 1 |
| Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP | 1 |
| Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Qin, LX | 1 |
| Tonini, GP | 1 |
| Brumback, BA; Campbell, LA; Castleberry, RP; Cohn, SL; Diller, L; Frantz, CN; London, WB; Matthay, KK; Seeger, RC | 1 |
| Brown, JL; Fang, W; Graham, TC; Omer, C; Pien, C; Thress, K; Zage, PE; Zeng, L; Zweidler-McKay, PA | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 2 |
| Ashikaga, T; Bergendahl, GM; Bingham, PM; Brard, L; Ferguson, WS; Heath, BW; Higgins, TJ; Homans, AC; Kamen, BA; Lenox, SR; Saulnier Sholler, GL; Singh, AP; Slavik, MA | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Cohn, SL; London, WB; Matthay, KK; Naranjo, A; Park, JR; Santana, VM; Scott, JR; Shaw, PJ; Stewart, CF | 1 |
| Loos, WJ; Mathijssen, RH; Verweij, J | 1 |
| Deméocq, F; Halle, P; Isfan, F; Kanold, J; Kelly, A; Lang, P; Marabelle, A; Merlin, E; Paillard, C; Rochette, E; Tchirkov, A | 1 |
| Chang, MN; Hou, W; Shuster, JJ | 1 |
| Badgett, TC; Chen, QR; Cheuk, AT; Khan, J; Song, YK; Tsang, PS; Wei, JS | 1 |
| Cantilena, S; D'Acunto, WC; Gnemmi, I; Sala, A; Sottile, F | 1 |
| Babich, JW; Boyd, M; Champion, S; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL; Tesson, M | 1 |
| Davidoff, AM; Hartwich, J; Morton, C; Ng, CY; Orr, WS; Spence, Y | 1 |
| Cheung, NK; Kramer, K; Kushner, BH | 1 |
| Biasotti, S; De Bernardi, B; Garaventa, A; Haupt, R; Luksch, R; Mastrangelo, S; Pizzitola, MR; Podda, M; Prete, A; Severi, G; Viscardi, E | 1 |
| Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM | 1 |
| Castleberry, R; Joshi, V; Kletzel, M; Kretschmar, CS; London, WB; Marcus, R; Murray, K; Smith, EI; Thorner, P | 1 |
| Chang, YC; Flux, GD; Gaze, MN; Mairs, RJ; Meller, ST; Saran, FH | 1 |
| Beppu, K; Linehan, WM; Nakamura, K; Rapisarda, A; Thiele, CJ | 1 |
| Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG | 1 |
| Billups, CA; Davidoff, AM; Furman, WL; Hoffer, F; Houghton, PJ; Santana, VM; Stewart, CF | 1 |
| Chang, MN; London, WB | 1 |
| Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M | 1 |
| Angerson, WJ; Boyd, M; Clark, AM; Cosimo, E; Gaze, MN; Mairs, RJ; McCluskey, AG; Ross, SC | 1 |
| Cheung, NK; Danis, K; Kernan, NA; Kramer, K; Kushner, BH; Modak, S; Reich, LM | 1 |
| Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA | 1 |
| Chuansumrit, A; Hongeng, S; Pakakasama, S; Sirachainan, N; Tuntiyatorn, L; Visudtibhan, A | 1 |
| Forman, E; Greenlaw, C; Kalkunte, S; McCarten, K; Saulnier Sholler, GL | 1 |
| Davidoff, AM; Dickson, PV; Fraga, CH; Hagedorn, NL; Hamner, JB; Ng, CY; Stewart, CF | 1 |
| Berthold, F; Hero, B; Klingebiel, T; Längler, A; Simon, T | 1 |
| Berthold, F; Claviez, A; Frühwald, MC; Harnischmacher, U; Hero, B; Jorch, N; Längler, A; Simon, T | 1 |
| Barnhart, JR; Grigoryan, RS; Keshelava, N; Reynolds, CP; Yang, B | 1 |
| DeClerck, YA; Groshen, SG; Moats, RA; Nelson, MD; Peng, H; Reynolds, CP; Sohara, Y; Ye, W | 1 |
| Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM | 1 |
| Panetta, JC; Santana, VM; Schaiquevich, P; Stewart, CF | 1 |
| Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Bleyer, WA; Gillespie, A; Krailo, MD; Needle, MN; Poplack, DG; Reaman, GH; Sato, JK | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Luo, X; Poquette, C; Richmond, LB; Santana, VM; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Inaba, M; Nomura, T; Ohnishi, Y; Sugiyama, Y; Tsuruo, T; Ueyama, Y | 1 |
| Cheshire, PJ; Danks, MK; Hanna, SK; Houghton, PJ; Hulstein, JL; Kirstein, M; Stewart, CF; Walsh, J; Zamboni, WC | 1 |
| Cheshire, PJ; de Graaf, SS; George, EO; Houghton, PJ; Ma, M; Poquette, CA; Richmond, LB; Stewart, CF; Thompson, J | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Kihl, BK; Middlemas, DS; Moody, NM | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Meyers, PA; Wollner, N | 1 |
| Gooley, T; Hawkins, D; Lindsley, K; Matthay, KK; Park, JR; Sanders, JE; Slattery, J; Villablanca, JG | 1 |
| Cheshire, PJ; Danks, MK; Guichard, SM; Houghton, PJ; Lorsbach, R; Poquette, CA; Ragsdale, ST; Richmond, LB; Thompson, J; Webber, B | 1 |
| Bernstein, ML; Harris, MB; Hayashi, R; Kepner, JL; Saylors, RL; Stine, KC; Sullivan, J; Vietti , TJ; Wall, DA | 1 |
| Boulad, F; Calleja, E; Cheung, NK; Dunkel, IJ; Kramer, K; Kushner, BH | 1 |
| Huang, J; Kandel, JJ; Kim, ES; Manley, CA; McCrudden, KW; Middlesworth, W; Soffer, SZ; Yamashiro, DJ; Yokoi, A | 1 |
| Houghton, PJ; Santana, VM | 1 |
3 review(s) available for topotecan and Neuroblastoma
| Article | Year |
|---|---|
Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neuroblastoma; Observational Studies as Topic; Radiopharmaceuticals; Thyroid Diseases; Topotecan | 2017 |
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Europe; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Vincristine | 2017 |
[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Combined Modality Therapy; DNA Damage; Enzyme Inhibitors; Humans; Neuroblastoma; Radiopharmaceuticals; Topoisomerase I Inhibitors; Topotecan | 2005 |
23 trial(s) available for topotecan and Neuroblastoma
| Article | Year |
|---|---|
Phase II study of
Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Young Adult | 2023 |
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial.
Topics: Bayes Theorem; Body Surface Area; Child; Cyclophosphamide; Humans; Neuroblastoma; Topotecan | 2023 |
Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Metastasis; Neuroblastoma; Risk Factors; Topotecan | 2018 |
Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Topotecan; Transplantation, Autologous | 2013 |
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Recurrence; Temozolomide; Topotecan; Young Adult | 2014 |
Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Topotecan; Transplantation Conditioning | 2015 |
HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Topics: 3-Iodobenzylguanidine; Adult; Caregivers; Child; Female; France; Humans; Iodine Radioisotopes; Male; Neoplasm Recurrence, Local; Neuroblastoma; Radiation Exposure; Radiometry; Topoisomerase I Inhibitors; Topotecan | 2017 |
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Causality; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Models, Statistical; Neuroblastoma; Prognosis; Recurrence; Risk Factors; Topotecan; Treatment Outcome; Young Adult | 2010 |
A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Maximum Tolerated Dose; Neuroblastoma; Nifurtimox; Recurrence; Topotecan; Treatment Outcome | 2011 |
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Male; Neuroblastoma; Pilot Projects; Topoisomerase I Inhibitors; Topotecan | 2011 |
A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease Progression; Doxorubicin; Female; Humans; Infant; Male; Neuroblastoma; Survival Analysis; Topotecan; Treatment Outcome; Vincristine | 2003 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome | 2004 |
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan | 2004 |
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Disease Progression; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Male; Neuroblastoma; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Topotecan; Treatment Outcome | 2005 |
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Thiotepa; Topotecan; Treatment Failure | 2006 |
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome | 2006 |
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan | 1998 |
Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Neuroblastoma; Pilot Projects; Salvage Therapy; Sarcoma; Topotecan | 2000 |
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
Topics: Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Glioma; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan | 2000 |
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Topotecan | 2001 |
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neuroblastoma; Radiotherapy, Adjuvant; Remission Induction; Thiotepa; Topotecan; Treatment Outcome | 2001 |
68 other study(ies) available for topotecan and Neuroblastoma
| Article | Year |
|---|---|
Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Child; Chronic Disease; Cyclophosphamide; Humans; Mice; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; Topotecan | 2023 |
Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclophosphamide; Gene Expression Regulation, Neoplastic; Heterografts; Homeodomain Proteins; Humans; Mice; N-Acetylgalactosaminyltransferases; N-Myc Proto-Oncogene Protein; Neuroblastoma; Precision Medicine; Topotecan; Transcription Factors; Transcriptome; Tyrosine 3-Monooxygenase | 2020 |
Recurrent Subconjunctival Hemorrhage in a Child With an Orbital Mass.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Eye Hemorrhage; Female; Humans; Infant; Neuroblastoma; Orbital Neoplasms; Recurrence; Topotecan; Treatment Outcome; Ultrasonography | 2021 |
Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Doxorubicin; Female; Humans; Male; Neuroblastoma; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Topotecan; Transplantation, Autologous; Vincristine | 2021 |
Venetoclax-based Rational Combinations are Effective in Models of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cyclophosphamide; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; N-Myc Proto-Oncogene Protein; Neuroblastoma; Sulfonamides; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
A 12-Month-Old Boy With Bilateral Facial Swelling and Proptosis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Exophthalmos; Humans; Infant; Magnetic Resonance Imaging; Male; Neuroblastoma; Orbital Cellulitis; Orbital Neoplasms; Skull Neoplasms; Sphenoid Bone; Stem Cell Transplantation; Topotecan | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
Dosimetry-based high-activity therapy with
Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult | 2019 |
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Topics: Animals; Cell Death; Child; Child, Preschool; Drug Synergism; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infant; Male; Mice; Mice, Nude; Neuroblastoma; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Signal Transduction; Sphingolipids; Sphingosine; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2013 |
Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Maintenance Chemotherapy; Male; Neoplasm Staging; Neuroblastoma; Topotecan; Treatment Outcome | 2013 |
[Management of refractory neuroblastoma with high-dose topotecan plus cyclophosphamide and vincristine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Neuroblastoma; Topotecan; Vincristine | 2014 |
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Induction Chemotherapy; Infant; Isotretinoin; Male; Neoadjuvant Therapy; Neoplasm Staging; Neuroblastoma; Neurosurgical Procedures; Pilot Projects; Prospective Studies; Radiotherapy; Thiotepa; Topotecan; Treatment Outcome; Vincristine | 2015 |
Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.
Topics: Aerobiosis; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Glycolysis; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nifurtimox; Nuclear Proteins; Oncogene Proteins; Oxidative Stress; Proto-Oncogene Mas; Reactive Oxygen Species; Topotecan | 2015 |
Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Cell Line, Tumor; Cluster Analysis; Dose-Response Relationship, Drug; Doxorubicin; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitochondrial Proteins; Molecular Chaperones; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Oncogene Proteins; Software; Topotecan; Transcriptome | 2015 |
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Immunocompromised Host; Inhibitory Concentration 50; Isotretinoin; MAP Kinase Signaling System; Mice; Neoplasm Proteins; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2015 |
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Crizotinib; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Mice, SCID; Mutation; Neuroblastoma; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Topotecan; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cellular Senescence; Female; Fluorescent Antibody Technique; Gene Amplification; Humans; In Vitro Techniques; Mice; N-Myc Proto-Oncogene Protein; Neuroblastoma; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays | 2016 |
Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan.
Topics: Anilides; Animals; Apoptosis; Cell Proliferation; Drug Therapy, Combination; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Suppressive effect of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; DNA Replication; DNA, Viral; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Naphthoquinones; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Virus Replication | 2016 |
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Chick Embryo; Deferoxamine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; Neuroblastoma; Promoter Regions, Genetic; Time Factors; Topotecan; Transcription, Genetic; Transcriptional Activation; Vascular Endothelial Growth Factor A | 2008 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2008 |
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; Glioma; Mice; Mice, Nude; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Radiopharmaceuticals; Topotecan; Treatment Outcome | 2008 |
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Mice; Neuroblastoma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2009 |
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carboplatin; Cell Adhesion; Cell Line, Tumor; Doxorubicin; Drug Synergism; Flow Cytometry; Gangliosides; Humans; Immunotherapy; Microscopy, Fluorescence; Neuroblastoma; Topotecan | 2009 |
EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mutation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured | 2009 |
Blasting neuroblastoma using optimal control of chemotherapy.
Topics: Antineoplastic Agents; Child; Computer Simulation; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Models, Immunological; Neuroblastoma; Neutrophils; Topotecan | 2009 |
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2010 |
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infant; Male; Neuroblastoma; Salvage Therapy; Topotecan; Vincristine | 2010 |
Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Evaluation, Preclinical; Etoposide; Humans; Neuroblastoma; Topotecan | 2010 |
The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neuroblastoma; Protein Kinase Inhibitors; Receptor, trkB; Signal Transduction; Substrate Specificity; Topotecan; Xenograft Model Antitumor Assays | 2011 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Determining the best dose for the individual patient.
Topics: Brain Neoplasms; Female; Humans; Induction Chemotherapy; Male; Neuroblastoma; Topoisomerase I Inhibitors; Topotecan | 2011 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms; Bone Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Doublecortin Domain Proteins; Haplotypes; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Male; Microtubule-Associated Proteins; Neoplasm, Residual; Neuroblastoma; Neuropeptides; Remission Induction; Temozolomide; Topotecan; Transcription Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2012 |
Improved two-stage tests for stratified phase II cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Endpoint Determination; Humans; Infant; Likelihood Functions; Neuroblastoma; Sample Size; Topotecan | 2012 |
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Mice; Mice, SCID; Microarray Analysis; Neuroblastoma; NF-kappa B; Pyrazines; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2012 |
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
Topics: Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; High-Throughput Screening Assays; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Protein Binding; Small Molecule Libraries; Topoisomerase I Inhibitors; Topotecan; Trans-Activators; Transcriptional Activation; Transgenes | 2012 |
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Combined Modality Therapy; DNA Breaks; Female; Flow Cytometry; Histones; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiopharmaceuticals; Topotecan; Tumor Stem Cell Assay | 2012 |
HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Injections, Intraperitoneal; Mice; Mice, SCID; Neuroblastoma; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden | 2013 |
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Topotecan; Treatment Outcome | 2003 |
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan | 2004 |
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Topics: 3-Iodobenzylguanidine; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Humans; Iodine Radioisotopes; Male; Neoplasm Metastasis; Neuroblastoma; Radiation Dosage; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Topotecan; Whole-Body Counting | 2005 |
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; Cell Line, Tumor; Culture Media, Conditioned; DNA-Binding Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Neuroblastoma; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Aryl Hydrocarbon; RNA, Small Interfering; Topotecan; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
One- and two-stage designs for stratified phase II clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Data Interpretation, Statistical; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Research Design; Topotecan | 2005 |
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan | 2005 |
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Complementary; Glioma; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Time Factors; Topotecan; Transfection | 2005 |
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Topics: Adolescent; Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Infant; Male; Melphalan; Mice; Neuroblastoma; Retrospective Studies; Thiotepa; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2007 |
Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.
Topics: Antineoplastic Agents; Catheters, Indwelling; Central Nervous System Neoplasms; Child, Preschool; Combined Modality Therapy; Humans; Infusions, Intravenous; Injections, Spinal; Male; Meningeal Neoplasms; Neuroblastoma; Topoisomerase I Inhibitors; Topotecan | 2008 |
Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chagas Disease; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Neuroblastoma; Nifurtimox; Recurrence; Remission Induction; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Blood Vessels; Disease Models, Animal; Genetic Vectors; Interferon-beta; Mice; Neoplasm Transplantation; Neuroblastoma; Topotecan | 2007 |
Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzyl Compounds; Cell Line, Tumor; Child; DNA Damage; DNA, Single-Stranded; Enzyme Inhibitors; Fenretinide; Flow Cytometry; Gamma Rays; Humans; Hydrocarbons, Fluorinated; Hydrogen Peroxide; In Situ Nick-End Labeling; Melphalan; Neuroblastoma; Oxidants; Reactive Oxygen Species; Topotecan | 2007 |
The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Caspase 3; Cell Growth Processes; Cell Survival; Cyclophosphamide; Diphosphonates; Enzyme Activation; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Osteoclasts; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Topotecan; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome | 2007 |
Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Drug Administration Schedule; History, Ancient; Humans; Infant, Newborn; Models, Theoretical; Neuroblastoma; Topotecan | 2008 |
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous | 1997 |
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Marrow Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mice; Mice, Inbred CBA; Neuroblastoma; Retroperitoneal Space; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous | 1998 |
Re: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Mice; Neuroblastoma; Reproducibility of Results; Topotecan; Transplantation, Heterologous; Treatment Outcome | 1998 |
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Topics: Animals; Chromatography, High Pressure Liquid; Extracellular Space; Female; Humans; Immunosuppression Therapy; Mice; Mice, Inbred CBA; Microdialysis; Models, Biological; Neuroblastoma; Thymectomy; Tissue Distribution; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Whole-Body Irradiation | 1999 |
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Child; Drug Resistance, Neoplasm; Female; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Neuroblastoma; Rhabdomyosarcoma; Thymectomy; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine; Whole-Body Irradiation | 1999 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents.
Topics: Antineoplastic Agents; Brain-Derived Neurotrophic Factor; Cisplatin; DNA Damage; DNA, Neoplasm; Doxorubicin; Gamma Rays; Humans; Neuroblastoma; Neuroprotective Agents; Topotecan; Tumor Cells, Cultured | 1999 |
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Mice; Mice, SCID; Neuroblastoma; Topotecan; Tumor Cells, Cultured; Vincristine | 2001 |
Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Endothelial Growth Factors; Enzyme Inhibitors; Female; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Clinical trials using irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2002 |